During this webinar, Dr. Matt Kaeberlein will provide an overview of translational geroscience, which he believes will become the paradigm for the practice of medicine in the 21st century. He will also discuss recent work with one such intervention, the drug rapamycin, and its potential to enhance healthspan in companion dogs and people.

Biological age is the greatest risk factor for nearly every major cause of death and disability, including COVID-19. Yet, traditional biomedical research and clinical approaches have generally focused on waiting until people are sick and treating individual diseases one at a time. Attempts to cure age-related diseases have proven unsuccessful, and the impact of “disease-first” approaches continue to be incremental. Recent advances in understanding them mechanisms linking biological aging to disease, or geroscience, have identified interventions that directly target the molecular hallmarks of aging. Unlike disease-specific approaches, such interventions have the potential to prevent multiple diseases of aging simultaneously, thereby greatly enhancing healthspan and lifespan for most individuals.

Key Topics Include:

  • Aging is a biological process that is under the control of both genetic and environmental factors
  • The biological mechanisms of aging are becoming better understood and can be formalized as nine “Hallmarks of Aging”
  • Several interventions have been identified that slow or reverse biological aging in laboratory animals
  • The drug rapamycin increases lifespan and reverses several functional declines associated with aging in mammals


Laboratory Medicine and Pathology
University of Washington

Dr. Matt Kaeberlein is a Professor of Laboratory Medicine and Pathology at the University of Washington School of Medicine. Dr. Kaeberlein’s research interests are focused on biological mechanisms of aging in order to facilitate translational interventions that promote healthspan and improve quality of life.

Additional Content From American Physiological Society

Myeloid Cells and Cardiovascular Health

Myeloid Cells and Cardiovascular Health

Dr. Matthias Nahrendorf discusses current concepts of cell supply by the hematopoietic system, highlights open questions, and describes imaging tools for studying monocytes, macrophages and their progenitors.

Related Content

Aging and Bone Health

Aging and Bone Health

In this webinar, Dr. Joy Wu will review the pathophysiology of bone loss with aging, in particular the imbalance between bone formation by osteoblasts and bone resorption by osteoclasts. She will discuss stem cell sources of osteoblasts, anabolic signaling pathways, and targeting inflammation and senescence.